Adalvo announces the successful DCP approval for Ivermectin 10mg/g (1% strength) topical cream. This broadens our dermatology portfolio with a high-value treatment option for rosacea.
Based on the reference brand Soolantra® (Galderma), Ivermectin cream is indicated for the treatment of inflammatory lesions, such as pimples and spots, associated with rosacea in adult patients.
According to IQVIA, Ivermectin generated some $202 million in global sales in 2024, reflecting its enduring clinical and commercial relevance.
With this approval, Adalvo is well-positioned to pursue launches across major EU markets, supported by a clearly defined regulatory and IP strategy. This milestone further highlights Adalvo's ability to deliver complex, partner-ready dermatology assets that balance medical need, commercial opportunity, and timely market entry.
Ivermectin topical cream now joins Adalvo’s expanding dermatology portfolio, which also includes Adapalene Gel, Adapalene + Benzoyl Peroxide Gel, and Tacrolimus Ointment.
For licensing or commercial opportunities within Adalvo’s dermatology portfolio, contact the team today.